Publications by authors named "Hadiya Manzoor"
Article Synopsis
- Neonatal hypoxic-ischemic encephalopathy primarily impacts low- and middle-income countries, with therapeutic hypothermia often proving ineffective, highlighting a need for earlier treatment strategies.
- A study involved administering perinatal caffeine to near-term lambs undergoing severe hypoxia-ischemia, assessing its pharmacokinetics, safety, and efficacy in improving outcomes.
- Caffeine administration enhanced neurodevelopmental results and decreased inflammation and gray matter damage, suggesting it could be a viable treatment for affected neonates compared to previous studies on other medications.
Hemorrhagic shock is a major source of morbidity and mortality worldwide. While whole blood or blood product transfusion is a first-line treatment, maintaining robust supplies presents significant logistical challenges, particularly in austere environments. OMX is a novel nonhemoglobin (Hb)-based oxygen carrier derived from the H-NOX (heme-nitric oxide/oxygen binding) protein family.
View Article and Find Full Text PDFOriginally approved by the U.S. Food and Drug Administration (FDA) for its antihistamine properties, clemastine can also promote white matter integrity and has shown promise in the treatment of demyelinating diseases such as multiple sclerosis.
View Article and Find Full Text PDFBackground: Hypoxic-ischemic brain injury/encephalopathy affects about 1.15 million neonates per year, 96% of whom are born in low- and middle-income countries. Therapeutic hypothermia is not effective in this setting, possibly because injury occurs significantly before birth.
View Article and Find Full Text PDF